Isomorphic Labs has raised $600 million towards its ambition to leverage AI to reimagine and accelerate drug discovery.
The financing round was led by Thrive Capital, with participation from GV, and follow-on capital from existing investor Alphabet.
Isomorphic Labs aims to apply its AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programmes across multiple therapeutic areas and drug modalities.
“We’re excited to bring together a top-tier…
